Cargando…

Disease course following High Disease Activity Status revealed patterns in SLE

BACKGROUND: We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited infor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoi, Alberta, Koelmeyer, Rachel, Bonin, Julie, Sun, Ying, Kao, Amy, Gunther, Oliver, Nim, Hieu T., Morand, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278658/ https://www.ncbi.nlm.nih.gov/pubmed/34261522 http://dx.doi.org/10.1186/s13075-021-02572-1

Ejemplares similares

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus
por: Nim, Hieu T., et al.
Publicado: (2019)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Associations of metabolic syndrome in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2020)

Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus
por: Northcott, Melissa, et al.
Publicado: (2022)

The performance of different classification criteria for systemic lupus erythematosus in a real-world rheumatology department
por: Tan, Brandon C H, et al.
Publicado: (2022)

Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE
por: Raghunath, Sudha, et al.
Publicado: (2021)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?
por: Boulos, Daniel, et al.
Publicado: (2017)

Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2019)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
por: Mende, Rachel, et al.
Publicado: (2018)

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
por: Morand, Eric F, et al.
Publicado: (2020)

CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses
por: Monaghan, Katherine A., et al.
Publicado: (2023)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
por: Croyle, Lucy, et al.
Publicado: (2015)

Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models
por: Reynolds, John A., et al.
Publicado: (2021)

Course of Neuropsychiatric Symptoms during Flares of Systemic Lupus Erythematosus (SLE)
por: Garrett, Gareth, et al.
Publicado: (2017)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Silent Burdens in Disease: Fatigue and Depression in SLE
por: Fonseca, R., et al.
Publicado: (2014)

Targeting DORIS Remission and LLDAS in SLE: A Review
por: Parra Sánchez, Agner R., et al.
Publicado: (2023)

Multiple Changes of Gene Expression and Function Reveal Genomic and Phenotypic Complexity in SLE-like Disease
por: Wilbe, Maria, et al.
Publicado: (2015)

Inflammation associated anemia and ferritin as disease markers in SLE
por: Vanarsa, Kamala, et al.
Publicado: (2012)

Genetics of SLE: Functional Relevance for Monocytes/Macrophages in Disease
por: Byrne, Jennifer C., et al.
Publicado: (2012)

23. Adult-onset Still’s disease presenting as SLE
por: Ellis, Natalya, et al.
Publicado: (2019)

SLE is not a one-size-fits-all disease
por: Ehrenstein, Michael R., et al.
Publicado: (2023)

Organ system-involvement in SLE and relationship with demographic factors, disease duration and health-related quality of life in childhood SLE
por: Moorthy, Lakshmi N, et al.
Publicado: (2012)

SLE and APS
por: Avcin, Tadej
Publicado: (2014)

Epigenetics in SLE
por: Hedrich, Christian Michael
Publicado: (2017)

PReS-FINAL-2351: Children with probable SLE by ACR criteria may need more aggressive lupus treatment early in the disease course
por: Patwardhan, A, et al.
Publicado: (2013)

Regulatory natural autoantibodies suppress inflammation and SLE disease activity
por: Silverman, GJ, et al.
Publicado: (2012)

Differences in disease phenotype and severity in SLE across age groups
por: Ambrose, N, et al.
Publicado: (2016)

Predictors of peripheral arterial disease in SLE change with patient’s age
por: Erdozain, Jose-Gabriel, et al.
Publicado: (2017)

Interferon pathway in SLE: one key to unlocking the mystery of the disease
por: Rönnblom, Lars, et al.
Publicado: (2019)

Treatment targets in SLE: remission and low disease activity state
por: Golder, Vera, et al.
Publicado: (2020)

Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk
por: Robinson, George A., et al.
Publicado: (2021)

Transcriptome sequencing reveals novel molecular features of SLE severity
por: Zhang, Xiaojing, et al.
Publicado: (2023)

Clinical associations of serum interleukin-17 in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2013)

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug development
por: Goteti, Kosalaram, et al.
Publicado: (2022)

Combinatorial Ranking of Gene Sets to Predict Disease Relapse: The Retinoic Acid Pathway in Early Prostate Cancer
por: Nim, Hieu T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_89mdg1ndbe0p1n2suopmgi6j4j